Navigation Links
AACR, BCRF award inaugural grants in translational breast cancer research
Date:10/11/2007

PHILADELPHIA Through the generous support of the Breast Cancer Research Foundation (BCRF), the American Association for Cancer Research (AACR) is pleased to announce the inaugural recipients of the 2007 BCRF-AACR Grants in Translational Breast Cancer Research. These grants provide direct support for innovative breast cancer research projects designed to accelerate the discovery, development, and application of new ways to treat breast cancer, or for preclinical research with direct therapeutic implications.

After careful evaluation and assessment by an esteemed scientific review committee, three researchers emerged as the winners of the 2007 BCRF-AACR Grants in Translational Breast Cancer Research. They are: Ingrid A. Mayer, M.D., Assistant Professor of Medicine Vanderbilt University Medical Center; Alana Welm, Ph.D., Assistant Professor of Oncological Sciences at the Huntsman Cancer Institute, University of Utah; and Douglas Yee, M.D., Cancer Center Director and Professor, University of MinnesotaTwin Cities.

The AACR congratulates Drs. Mayer, Welm and Yee on this outstanding achievement and applauds their efforts to translate their innovative research into potential treatments for breast cancer, said Margaret Foti, Ph.D., M.D. (h.c.), AACRs chief executive officer. We are deeply grateful to the Breast Cancer Research Foundation for its commitment to cutting-edge breast cancer research and look forward to a long-lasting partnership in supporting novel translational research.

Currently, an estimated 2 million Americans are living with or have been treated for breast cancer. Approximately 178,480 new breast cancer cases will be diagnosed this year, and about 40,460 will die from the disease. Translational research bridges the gap between laboratory research and patient care. The BCRF-AACR grant program has the vitally important goal of bringing scientific discoveries from the laboratory into breast cancer treatment protocols swiftly, safely and effectively.

Fifty-six grant applications were received and resulted in three awards, each for $233,333, to support promising research projects that could lead to individualized therapeutic options for breast cancer treatment in the near future.

Mayers research project, titled Combined Endocrine and ErbB Inhibition in ER+/HER2+ Breast Cancers, will address resistance to endocrine therapies. Through a Phase II study, she seeks to learn if the combination of an aromatase inhibitor with an EGFR/HER2 inhibitor will work better in preventing failure of tumors to respond to anti-hormonal treatment. Mayer hopes that her research will reduce mortality in patients with hormone-responsive HER2-positive breast cancer.

Welms research, The MSP Pathway as a Therapeutic Target in Aggressive Breast Cancer, will build upon her earlier studies which found that overexpression of the macrophage- stimulating protein (MSP) pathway drives progression of breast cancer. She validated the clinical relevance of this finding through gene expression data gathered from patients with early- stage breast cancer, showing that overexpression of three genes within the MSP pathway served as highly accurate indicators of poor prognosis in patients with early breast cancer. Her current research seeks to translate these findings to the clinic by developing a diagnostic test for overexpression of the MSP pathway as a biomarker for poor prognosis and to carry out preclinical tests of three MSP pathway inhibitors in order to block growth and/or metastasis of breast cancer.

Yee will look at Gene Expression Profiling to Predict Response to anti-IGF Therapy. This research builds upon his long-term goal of demonstrating that the insulin-like growth factor receptor (IGF1R) is an excellent target for breast cancer therapy. Yee hypothesizes that expression of specific insulin receptor substrate adaptor proteins link IGF1R to identifiable gene signatures and cancer phenotypes. To test this, Yee aims to develop gene expression profiles to predict which cancers are IGF-driven and, ultimately, which patients may best benefit from these inhibitors. His long-term goal is to use these discoveries to make the use of anti-IGF drugs more effective, and to create a better tool for making personalized therapeutic decisions for breast cancer.


'/>"/>

Contact: Jennifer Ryan
jennifer.ryan@aacr.org
267-646-0558
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. NJIT Presidential Award winner takes stem cell research another step
2. TGen awarded $7.1 million to accelerate brain disease research
3. Virtual microscopy project wins educational technology award
4. New NIAID grants strengthen national biodefense and emerging infectious diseases research network
5. Asian immigrants in NYC not receiving HIV education at religious institutions
6. Scientists win grants to develop $1,000 genome sequencing technology
7. Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance
8. A splice of the action: Translational role for WT1 isoform
9. Viral DNA sequence a possible trigger for breast cancer
10. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
11. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/25/2016)... 25, 2016  Glencoe Software, the world-leading supplier of ... industries, will provide the data management solution OMERO Plus ... Photo - ... Phenotypic analysis measures the characteristics and ... comparisons between states such as health and disease, the ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):
(Date:2/11/2016)...   BioInformant announces the February 2016 release ... Opportunities, Tools, and Technologies – Market Size, Segments, Trends, ... The first and only market ... BioInformant has more than a decade of historical information ... stem cell type. This powerful 175 page global strategic ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... cell treatment clinic in Quito, Ecuador. The new facility will provide advanced protocols ... patients from around the world. , The new GSCG clinic is headed ...
(Date:2/10/2016)... Feb. 10, 2016  The Maryland House of Delegates ... announced that University of Maryland School of Medicine Dean ... University of Maryland Medical System President and CEO ... Medallion," the highest honor given to the public by ... Dean Reece and Mr. Chrencik for their ...
(Date:2/10/2016)... New York, and New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it ... and develop new vaccines and immunotherapies for infectious diseases and cancer. ...
Breaking Biology Technology: